Fred Holdbrook

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

Bhupendra Khatri, Frederik Barkhof, Giancarlo Comi et al. · The Lancet Neurology · 2011 · 216 citations · Full text

Life Sciences, Neurology, Neuroimmunology +8

Body Weight Changes with β-Blocker Use: Results from GEMINI

Franz H. Messerli, David S.H. Bell, Vivian Fonseca et al. · The American Journal of Medicine · 2007 · 108 citations

Medicine, Cardiology, Pharmacotherapy +11

Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial

Raphael Schiffmann, Daniel G. Bichet, Ana Jovanović et al. · Orphanet Journal of Rare Diseases · 2018 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)

Benedikt Schoser, Priya S. Kishnani, Drago Bratkovic et al. · Journal of Neurology · 2024 · 27 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)

Barry J. Byrne, Benedikt Schoser, Priya S. Kishnani et al. · Journal of Neurology · 2023 · 20 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13